why choose us

First received: December 30, 2022

Clinical Trial: Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers

Study Status: Completed

Recruit Status: RECRUITING

Condition: Locally Advanced Salivary Gland Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Brief Summary: This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent).Darolutamide is in a class of medications called androgen receptor inhibitors.It works by blocking the effects of androgen (a male reproductive…

Read more